Allergy Therapeutics plc (LON:AGY) has strengthened its core intellectual property after the European Patent Office granted it a broad technology patent for its Microcrystalline Tyrosine (MCT) depot adjuvant manufacturing process.
The patent covers the novel manufacture and physiochemical characteristics of MTC in combination with one or more antigens, Allergy said.
The company had already been granted similar patents in the UK and in New Zealand for the MCT technology.
“We are pleased to expand this key patent and are excited by the potential for MCT as a core technology within our adjuvant portfolio to create novel and efficacious vaccines,” said chief executive Manuel Llobet.
“This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines.”
An adjuvant is a substance which enhances the body’s immune response to an antigen. In the case of MCT, it extends the time available for the immune system to process an antigen.
Recent data has shown that MCT has a synergistic effect when coupled with another adjuvant, Virus Like Particles.
This combined adjuvant system demonstrated positive efficacy in a malaria model in a study performed in collaboration with the University of Oxford.
Shares were up 5% in early deals on Wednesday.